The potential role of nemonoxacin for treatment of common infections
Journal
Expert Opinion on Pharmacotherapy
Journal Volume
16
Journal Issue
2
Pages
263-270
Date Issued
2015
Author(s)
Abstract
Introduction: Nemonoxacin, a novel non-uorinated quinolone, exhibits potent activity against Gram-positive bacteria, including MRSA and fluoroquinolone-resistant MRSA, Gram-negative and atypical pathogens. This agent also has a reduced propensity for resistance development in many kinds of pathogens. Areas covered: This article reviews currently available clinical and in vitro data that support the potential role of nemonoxacin for the treatment of common infectious diseases, including community-acquired pneumonia (CAP), Clostridium difficile infections (CDIs), acute bacterial skin and skin structure infections (ABSSSIs) and sexually transmitted diseases (STDs). One recent Phase II trial comparing either 500 mg or 750 mg oral nemonoxacin with 500 mg oral levofloxacin for mild to moderate CAP demonstrated that nemonoxacin had comparable clinical success with levofloxacin. Nemonoxacin showed lower MICs against clinical C. difficile isolates than commercially available fluoroquinolones, making it a potential therapeutic agent if novel formulations are developed to maintain a higher concentration in the human gut. For STDs, nemonoxacin also showed good activity against some common pathogens, such as Chlamydia trachomatis and Neisseria gonorrhoeae. Expert opinion: Although in vitro studies have shown promising results regarding the susceptibility to nemonoxacin of common pathogens causing CDIs, ABSSSIs and STDs, further clinical trials are needed to prove its efficacy. ? 2015 Informa UK, Ltd.
SDGs
Other Subjects
levofloxacin; nemonoxacin; quinoline derived antiinfective agent; antiinfective agent; levofloxacin; nemonoxacin; quinolone derivative; antimicrobial activity; Article; bacterial skin disease; Chlamydia trachomatis; Clostridium difficile infection; community acquired pneumonia; drug indication; human; minimum inhibitory concentration; Neisseria gonorrhoeae; phase 2 clinical trial (topic); sexually transmitted disease; Chlamydia Infections; Clostridium Infections; Community-Acquired Infections; drug combination; gonorrhea; Pneumonia, Bacterial; Skin Diseases, Bacterial; Anti-Bacterial Agents; Chlamydia Infections; Clostridium Infections; Community-Acquired Infections; Drug Therapy, Combination; Gonorrhea; Humans; Levofloxacin; Pneumonia, Bacterial; Quinolones; Skin Diseases, Bacterial
Type
journal article